Instituto de Investigación Sanitaria Hospital 12 de Octubre-ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2024

  1. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis

    Nephrology Dialysis Transplantation, Vol. 39, Núm. 2, pp. 328-340

2023

  1. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  2. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

    Kidney360, Vol. 4, Núm. 5, pp. 659-672

  3. Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy

    Kidney International Reports, Vol. 8, Núm. 8, pp. 1596-1604

  4. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

    Kidney International Reports, Vol. 8, Núm. 12, pp. 2754-2764

  5. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090

  6. Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation

    Nephrology Dialysis Transplantation, Vol. 38, Núm. 1, pp. 222-235

  7. Targeting complement in IgA nephropathy

    Clinical Kidney Journal, Vol. 16, pp. ii28-ii39

2022

  1. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 11, pp. 2128-2137

  2. Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function

    Clinical Kidney Journal, Vol. 15, Núm. 4, pp. 771-777

  3. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

    Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746